ICD patients with elevated defibrillation threshold: Clinical behavior and therapeutic alternatives;Portadores de CDI com limiar de desfibrilação elevado: Evolução clínica e alternativas terapêuticas

Arquivos Brasileiros de Cardiologia

Volumn 90, Issue 3, 2008, Pages

  De Lima, Carlos Eduardo Batista ^a,b   Martinelli Filho, Martino ^a   Silva, Rodrigo Tavares ^a   Tamaki, Wagner Tetsuji ^a   De Oliveira, Júlio Cesar ^a   Martins, Daniela Cabral ^a   Nishióka, Silvana Angelina D'Orio ^a   Pedrosa, Anísio Alexandre Andrade ^a   Siqueira, Sérgio Freitas ^a   Costa, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Death, sudden, cardiac; Defibrillation threshold, defibrillators, implantable

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CHAGAS DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DATA BASE; DEFIBRILLATION; DEFIBRILLATOR; ELECTRODE; EVOLUTION; FOLLOW UP; HEALTH BEHAVIOR; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HUMAN; IDIOPATHIC DISEASE; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE;

EID: 42049094895     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008000300004     Document Type: Article

References (32)

1. Zoll PM. Resuscitation of the heart in ventricular standstill by external electrical stimulation. N Engl J Med. 1952; 247: 768-71.
2. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980; 303: 322-4.
3. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335: 1933-40.
4. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmic Versus Implantable Defibrillators (Avid) Investigators. N Engl J Med. 1997; 337: 1576-83.
5. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. ICD versus drugs in cardiac arrest survivors: preliminary results of the cardiac arrest study. The CASH Investigators. Pacing Clin Electrophysiol. 1993; 16: 552-8.
6. Manolis AS, Tan-DeGuzman W, Lee MA, Rasteger H, Haffajee CI, Huang SKS, et al. Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator. Am Heart J. 1989; 118: 445-50.
7. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989; 13: 1353-61.
8. Marchlinski FE, Flores B, Miller JM, Gottlieb CD, Hargrove WC. 3rd. Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implatable cardioverter defibrillator. Am J Cardiol. 1988; 62: 393-8.
9. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Former M, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006; 48: 1064-108.
10. American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. ECC Committee, Subcommittees and Task Forces of the American Heart Association. Circulation. 2005; 112 (24 Suppl IV): 1-203.
11. International Liaison Committee on resuscitation. 2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with treatment recommendations. Circulation. 2005; 112 (Suppl III): III-1-III-136.
12. Strickberger SA, Man KC, Souza J, Zivin A, Weiss R, Knight BP, et al. A prospective evaluation of two defibrillation safety margin techniques in patients with low defibrillation energy requirements. J Cardiovasc Electrophysiol. 1998; 9: 41-6.
13. Gold MR, Olsovsky MR, Pelini MA, Peters RW, Shorofsky SR. Comparison of single and dual-coil active pectoral defibrillation systems. J Am Coll Cardiol. 1998; 31: 1391-4.
14. Friedman PA, Rasmussen MJ, Grice S, Trusty J, Glikson M, Stanton MS. Defibrillation thresholds are increased by right-sided implantation of totally transvenous implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 1999; 22: 1186-92.
15. Kasanuki H, Takeichi K. High defibrillation energy requirements: current management. Cardiac Electrophysiology Review. 2001; 5: 63-6.
16. Higgins SL, Rich DH, Haygood JR, Barone J, Greer SL, Meyer DB. ICD restudy: results and potential benefit from routine predischarge and 2-month evaluation. Pacing Clin Electrophysiol. 1998; 21: 410-7.
17. Stajduhar KC, Ott GY, Kron J, McAnulty JH, Oliver RP, Reynolds BT. Optimal electrode position for transvenous defibrillation: a prospective randomized study. J Am Coll Cardiol. 1996; 27: 90-4.
18. Gradaus R, Block M, Seidl K, Brunn J, Isgro F, Hammel D, et al. Defibrillation efficacy comparing a subcutaneous array electrode versus an "active can" implantable cardioverter-defibrillator and a subcutaneous array electrode in addition to an "active can" implantable cardioverter-defibrillator: results from Active Can versus Array Trials I and II. J Cardiovasc Electrophysiol. 2001; 12: 921-7.
19. Kuhlkamp V, Dornberger V, Khalighi K, Mewis C, Suchalla R, Ziemer G, et al. Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold. Pacing Clin Electrophysiol. 1998; 21 (12): 2596-605.
20. Rattes MF, Jones DL, Sharma AD, Klein GJ. Defibrillation threshold: a simple and quantitative estimate of the ability to defibrillate. Pacing Clin Eletrophysiol. 1987; 10: 70-7.
21. Gold MR, Higgins S, Klein R, Gilliam FR, Kopelman H, Hessen S, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation. 2002; 105: 2043-8.
22. Neuzner J, Liebrich A, Jung J, Himmrich E, Pitschner HF, Winter J, et al. Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: results of the prospective, randomized, multicenter low energy Endotak trial. Am J Cardiol. 1999; 83: 34D-9D.
23. Theuns DAMJ, Szili-Torok T, Jordaens LJ. Defibrillation efficacy testing: long-term follow-up and mortality. Europace. 2005; 7 (6): 509-15.
24. Strickberger SA, Klein GJ. Is defibrillation testing required for defibrillator implantation? J Am Coll Cardiol. 2004; 44: 88-91.
25. Marchlinski FE, Flores B, Miller JM, Gottlieb. CD, Hargrove WC. Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implantable cardioverter defibrillator. Am J Cardiol. 1988; 62: 393-8.
26. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of b-blockers, amiodarone plus b-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. The OPTIC Study: a randomized trial. JAMA. 2006; 295: 165-71.
27. Huang SKS, Tan de Guzman WL, Chenarides JG, Okike O, Vander Salm TJ: Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J. 1991; 122: 720-7.
28. Boriani G, Biffi M, Frabetti L, Maraschi M, Branzi A. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol. Heart Lung. 2000; 29 (6); 412-6.
29. Epstein AE, Ellenbogen KA, Kirk KA, Kay GN, Dailey SM, Plumb VJ. Clinical characteristics and outcome of patients with high defibrillation thresholds. Circulation. 1992; 86: 1206-16.
30. Windecker S, Ideker RE, Plumb VJ, Kay GN, Walcott GP, Epstein AE, et al. The influence of ventricular fibrillation duration on defibrillation efficacy using biphasic waveforms in humans. J Am Coll Cardiol. 1999; 33: 33-8.
31. Gold MR, Higgins S, Klein R, Roosevelt FG ,Harry K, Scott H, et al. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation. primary results from the low energy safety study (LESS). Circulation. 2002; 105: 2043-8.
32. Hohnloser SH, Paul D, Roberts R, Michael G, Israel CW, Eric F, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006; 114: 104-9.